2015 Exits: Biotech’s Big Year
This article was originally published in Start Up
Fewer companies went public in 2015 than during the peak year of 2014, but on average 2015’s US IPO crop raised more money and at better valuations. And thanks to a jump in private biotech acquisition volume and valuations, investors enjoyed a tremendous year for biotech exits.
Register for our free email digests: